nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

26.05.2022 | Original Article

Periplocin Alleviates Cardiac Remodeling in DOCA-Salt–Induced Heart Failure Rats

verfasst von: Jiameng Hao, Liping Chang, Dandong Wang, Chuanyuan Ji, Shaolan Zhang, Yunlong Hou, Yiling Wu

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a common public health problem associated with increased morbidity and long-term mortality. However, effective treatment for HFpEF was not discovered yet. In the present study, we aimed to decipher the effects of Periplocin on DOCA-induced heart failure rats and explore the possible underlying mechanisms. We demonstrated that Periplocin could significantly attenuate cardiac structural remodeling and improve cardiac diastolic function. Of note, Periplocin significantly inhibited the recruitment of inflammatory and immune cells and decreased the expression of serum inflammatory cytokines. Meanwhile, Periplocin had the effect of cardiac glycosides to improve cardiomyocyte contractility and calcium transient amplitude. These findings indicate that Periplocin might be a potential medicine to treat HFpEF in patients.

Graphical abstract

Upadhya, B., & Kitzman, D. W. (2020). Heart failure with preserved ejection fraction: New approaches to diagnosis and management. Clinical Cardiology, 43(2), 145–155. https://doi.org/10.1002/clc.23321CrossRefPubMed

Shear, F. E. (2019). Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: Clinical perspectives. American Journal of Cardiovascular Diseases, 9(5), 91–108.

Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017). Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. Journal of the American College of Cardiology, 70(20), 2476–2486. https://doi.org/10.1016/j.jacc.2017.08.074CrossRefPubMed

Minamisawa, M., Claggett, B., Suzuki, K., Hegde, S. M., Shah, A. M., Desai, A. S., Lewis, E. F., Shah, S. J., Sweitzer, N. K., Fang, J. C., Anand, I. S., O’Meara, E., Rouleau, J. L., Pitt, B., Pfeffer, M. A., Solomon, S. D., & Vardeny, O. (2021). Association of hyper-polypharmacy with clinical outcomes in heart failure with preserved ejection fraction. Circulation. Heart Failure, 14(11), e8293. https://doi.org/10.1161/CIRCHEARTFAILURE.120.008293CrossRef

Simmonds, S. J., Cuijpers, I., Heymans, S., Jones, E. (2020). Cellular and molecular differences between HFpEF and HFrEF: A step ahead in an improved pathological understanding. Cells-Basel 9(1). https://doi.org/10.3390/cells9010242

Campanharo, F. F., Cecatti, J. G., Haddad, S. M., Parpinelli, M. A., Born, D., Costa, M. L., & Mattar, R. (2015). The impact of cardiac diseases during pregnancy on severe maternal morbidity and mortality in Brazil. PLoS One, 10(12), e144385. https://doi.org/10.1371/journal.pone.0144385CrossRef

Rossi, A., Gheorghiade, M., Triposkiadis, F., Solomon, S. D., Pieske, B., & Butler, J. (2014). Left atrium in heart failure with preserved ejection fraction: Structure, function, and significance. Circulation Heart Failure, 7(6), 1042–1049. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001276CrossRefPubMed

van Empel, V., & Brunner-La, R. H. (2015). Inflammation in HFpEF: Key or circumstantial? International Journal of Cardiology, 189, 259–263. https://doi.org/10.1016/j.ijcard.2015.04.110CrossRefPubMed

Singh, S., Moore, H., Karasik, P. E., Lam, P. H., Wopperer, S., Arundel, C., Tummala, L., Anker, M. S., Faselis, C., Deedwania, P., Morgan, C. J., Zeng, Q., Allman, R. M., Fonarow, G. C., & Ahmed, A. (2020). Digoxin initiation and outcomes in patients with heart failure (HFrEF and HFpEF) and atrial fibrillation. American Journal of Medicine, 133(12), 1460–1470. https://doi.org/10.1016/j.amjmed.2020.05.030CrossRefPubMed

10.

Gheorghiade, M., & Ferguson, D. (1991). Digoxin. A neurohormonal modulator in heart failure? Circulation, 84(5), 2181–2186. https://doi.org/10.1161/01.cir.84.5.2181CrossRefPubMed

11.

Ferguson, D. W., Berg, W. J., Sanders, J. S., Roach, P. J., Kempf, J. S., & Kienzle, M. G. (1989). Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circulation, 80(1), 65–77. https://doi.org/10.1161/01.cir.80.1.65CrossRefPubMed

12.

Vogel, R., Kirch, D., LeFree, M., Frischknecht, J., & Steele, P. (1977). Effects of digitalis on resting and isometric exercise myocardial perfusion in patients with coronary artery disease and left ventricular dysfunction. Circulation, 56(3), 355–359. https://doi.org/10.1161/01.cir.56.3.355CrossRefPubMed

13.

Firth, B. G., Dehmer, G. J., Corbett, J. R., Lewis, S. E., Parkey, R. W., & Willerson, J. T. (1980). Effect of chronic oral digoxin therapy on ventricular function at rest and peak exercise in patients with ischemic heart disease. American Journal of Cardiology, 46(3), 481–490. https://doi.org/10.1016/0002-9149(80)90019-3CrossRefPubMed

14.

Sonnenblick, E. H., Williams, J. J., Glick, G., Mason, D. T., & Braunwald, E. (1966). Studies on digitalis XV. Effects of cardiac glycosides on myocardial force-velocity relations in the nonfailing human heart. Circulation, 34(3), 532–539. https://doi.org/10.1161/01.cir.34.3.532CrossRefPubMed

15.

Adamantidis, M. M., Duriez, P. R., Vincent, A. C., & Dupuis, B. A. (1983). Digoxin-induced toxicity and experimental atrioventricular block in dogs. Relation between ventricular arrhythmias and oscillatory afterpotentials. Journal of Pharmacology, 14(3), 333–349.

16.

Capasso, J. M., Puntillo, E., Halpryn, B., Olivetti, G., Li, P., & Anversa, P. (1992). Amelioration of effects of hypertension and diabetes on myocardium by cardiac glycoside. American Journal of Physiology, 262(3 Pt 2), H734–H742. https://doi.org/10.1152/ajpheart.1992.262.3.H734CrossRefPubMed

17.

Zile, M. R., & Brutsaert, D. L. (2002). New concepts in diastolic dysfunction and diastolic heart failure: Part II: Causal mechanisms and treatment. Circulation, 105(12), 1503–1508. https://doi.org/10.1161/hc1202.105290CrossRefPubMed

18.

National Pharmacopoeia Committee. (2020). Chinese Pharmacopoeia-Volume I (pp. 1088–1089). Beijing: China Medical Science and Technology Press.

19.

Xie, G., Sun, L., Li, Y., Chen, B., & Wang, C. (2021). Periplocin inhibits the growth of pancreatic cancer by inducing apoptosis via AMPK-mTOR signaling. Cancer Medicine, 10(1), 325–336. https://doi.org/10.1002/cam4.3611CrossRefPubMed

20.

Zhang, X., Nan, H., Guo, J., Yang, S., & Liu, J. (2020). Periplocin induces apoptosis and inhibits inflammation in rheumatoid arthritis fibroblast-like synoviocytes via nuclear factor kappa B pathway. IUBMB Life, 72(9), 1951–1959. https://doi.org/10.1002/iub.2328CrossRefPubMed

21.

Haohao, C., Xiaoming, W., Guixiang, P., & Tingting, L. (2017). Detection of the human plasma protein binding rate of periplocin, periplocymarin and periplogenin. Journal of Liaoning University of TCM, 19(07), 32–35. https://doi.org/10.13194/j.issn.1673-842x.2017.07.007CrossRef

22.

Zhang, W. J., Song, Z. B., Bao, Y. L., Li, W. L., Yang, X. G., Wang, Q., Yu, C. L., Sun, L. G., Huang, Y. X., & Li, Y. X. (2016). Periplogenin induces necroptotic cell death through oxidative stress in HaCaT cells and ameliorates skin lesions in the TPA- and IMQ-induced psoriasis-like mouse models. Biochemical Pharmacology, 105, 66–79. https://doi.org/10.1016/j.bcp.2016.02.001CrossRefPubMed

23.

Da, S., Jing, Z., Jin-tang, C., Kun, Z., & Yan-ru, D. (2011). Comparison of the effect of cardiac glycosides in periplocae cortex on isolated heart in rats. Chinese Archives of Traditional Chinese Medicine, 29(12), 2633–2635. https://doi.org/10.13193/j.archtcm.2011.12.35.sund.054CrossRef

24.

Li, M., Yan-su, J., Juan, H., Fang, L., & Yi, W. (2008). Effect of glucoperiplocymarin on left ventricular structure and function in chronic heart failure rats by color doppler- echocardiography. Journal of Tianjin University of Traditional Chinese Medicine, 02, 81–83.

25.

Silberman, G. A., Fan, T. H., Liu, H., Jiao, Z., Xiao, H. D., Lovelock, J. D., Boulden, B. M., Widder, J., Fredd, S., Bernstein, K. E., Wolska, B. M., Dikalov, S., Harrison, D. G., & Dudley, S. J. (2010). Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation, 121(4), 519–528. https://doi.org/10.1161/CIRCULATIONAHA.109.883777CrossRefPubMedPubMedCentral

26.

Gao, Y., Zhang, K., Zhu, F., Wu, Z., Chu, X., Zhang, X., Zhang, Y., Zhang, J., & Chu, L. (2014). Salvia miltiorrhiza (Danshen) inhibits L-type calcium current and attenuates calcium transient and contractility in rat ventricular myocytes. J Ethnopharmacol, 158 Pt A, 397–403. https://doi.org/10.1016/j.jep.2014.10.049CrossRefPubMed

27.

Salem, K. A., Qureshi, A., Ljubisavijevic, M., Oz, M., Isaev, D., Hussain, M., & Howarth, F. C. (2010). Alloxan reduces amplitude of ventricular myocyte shortening and intracellular Ca2+ without altering L-type Ca2+ current, sarcoplasmic reticulum Ca2+ content or myofilament sensitivity to Ca2+ in Wistar rats. Molecular and Cellular Biochemistry, 340(1–2), 115–123. https://doi.org/10.1007/s11010-010-0408-7CrossRefPubMed

28.

Lavelle, G. C., Sturman, L., & Hadlow, W. J. (1972). Isolation from mouse spleen of cell populations with high specific infectivity for scrapie virus. Infection and Immunity, 5(3), 319–323. https://doi.org/10.1128/iai.5.3.319-323.1972CrossRefPubMedPubMedCentral

29.

Iyer, A., Chan, V., & Brown, L. (2010). The DOCA-salt hypertensive rat as a model of cardiovascular oxidative and inflammatory stress. Current Cardiology Reviews, 6(4), 291–297. https://doi.org/10.2174/157340310793566109CrossRefPubMedPubMedCentral

30.

Andersen, M. J., & Borlaug, B. A. (2014). Invasive hemodynamic characterization of heart failure with preserved ejection fraction. Heart Failure Clinics, 10(3), 435–444. https://doi.org/10.1016/j.hfc.2014.03.001CrossRefPubMed

31.

Glezeva, N., & Baugh, J. A. (2014). Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Failure Reviews, 19(5), 681–694. https://doi.org/10.1007/s10741-013-9405-8CrossRefPubMed

32.

Loch, D., Hoey, A., & Brown, L. (2006). Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat. Clinical and Experimental Hypertension, 28(5), 475–488. https://doi.org/10.1080/10641960600798754CrossRefPubMed

33.

Connelly, K. A., Zhang, Y., Visram, A., Advani, A., Batchu, S. N., Desjardins, J. F., Thai, K., & Gilbert, R. E. (2019). Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction. JACC Basic Transl Sci, 4(1), 27–37. https://doi.org/10.1016/j.jacbts.2018.11.010CrossRefPubMedPubMedCentral

34.

Konstam, M. A., Kramer, D. G., Patel, A. R., Maron, M. S., & Udelson, J. E. (2011). Left ventricular remodeling in heart failure: Current concepts in clinical significance and assessment. JACC: Cardiovascular Imaging, 4(1), 98–108. https://doi.org/10.1016/j.jcmg.2010.10.008CrossRefPubMed

35.

Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. R., Dokainish, H., Edvardsen, T., Flachskampf, F. A., Gillebert, T. C., Klein, A. L., Lancellotti, P., Marino, P., Oh, J. K., Popescu, B. A., & Waggoner, A. D. (2016). Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography, 29(4), 277–314. https://doi.org/10.1016/j.echo.2016.01.011CrossRefPubMed

36.

Sharma, K., & Kass, D. A. (2014). Heart failure with preserved ejection fraction: Mechanisms, clinical features, and therapies. Circulation Research, 115(1), 79–96. https://doi.org/10.1161/CIRCRESAHA.115.302922CrossRefPubMedPubMedCentral

37.

Kass, D. A. (2000). Assessment of diastolic dysfunction. Invasive modalities. Cardiology Clinical, 18(3), 571–586. https://doi.org/10.1016/s0733-8651(05)70162-4CrossRef

38.

Yellin, E. L., & Meisner, J. S. (2000). Physiology of diastolic function and transmitral pressure-flow relations. Cardiology Clinics, 18(3), 411–433. https://doi.org/10.1016/s0733-8651(05)70153-3CrossRefPubMed

39.

Zile, M. R., Baicu, C. F., Ikonomidis, J. S., Stroud, R. E., Nietert, P. J., Bradshaw, A. D., Slater, R., Palmer, B. M., Van Buren, P., Meyer, M., Redfield, M. M., Bull, D. A., Granzier, H. L., & LeWinter, M. M. (2015). Myocardial stiffness in patients with heart failure and a preserved ejection fraction: Contributions of collagen and titin. Circulation, 131(14), 1247–1259. https://doi.org/10.1161/CIRCULATIONAHA.114.013215CrossRefPubMedPubMedCentral

40.

Iyer, A., Woodruff, T. M., Wu, M. C., Stylianou, C., Reid, R. C., Fairlie, D. P., Taylor, S. M., & Brown, L. (2011). Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats. Journal of Cardiovascular Pharmacology, 58(5), 479–486. https://doi.org/10.1097/FJC.0b013e31822a7a09CrossRefPubMed

41.

Zouein, F. A., de Castro, B. L., Da, C. D., Lindsey, M. L., Kurdi, M., & Booz, G. W. (2013). Heart failure with preserved ejection fraction: Emerging drug strategies. Journal of Cardiovascular Pharmacology, 62(1), 13–21. https://doi.org/10.1097/FJC.0b013e31829a4e61CrossRefPubMedPubMedCentral

42.

Nicoletti, A., Heudes, D., Mandet, C., Hinglais, N., Bariety, J., & Michel, J. B. (1996). Inflammatory cells and myocardial fibrosis: Spatial and temporal distribution in renovascular hypertensive rats. Cardiovascular Research, 32(6), 1096–1107. https://doi.org/10.1016/s0008-6363(96)00158-7CrossRefPubMed

43.

Nevers, T., Salvador, A. M., Grodecki-Pena, A., Knapp, A., Velazquez, F., Aronovitz, M., Kapur, N. K., Karas, R. H., Blanton, R. M., & Alcaide, P. (2015). Left ventricular T-cell recruitment contributes to the pathogenesis of heart failure. Circulation. Heart Failure, 8(4), 776–787. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002225CrossRefPubMedPubMedCentral

44.

Li, N., Bian, H., Zhang, J., Li, X., Ji, X., & Zhang, Y. (2010). The Th17/Treg imbalance exists in patients with heart failure with normal ejection fraction and heart failure with reduced ejection fraction. Clinica Chimica Acta, 411(23–24), 1963–1968. https://doi.org/10.1016/j.cca.2010.08.013CrossRef

45.

Lu, M., Qin, X., Yao, J., Yang, Y., Zhao, M., & Sun, L. (2020). Th17/Treg imbalance modulates rat myocardial fibrosis and heart failure by regulating LOX expression. Acta Psychologica, 230(3), e13537. https://doi.org/10.1111/apha.13537CrossRef

46.

Keck, M., Flamant, M., Mougenot, N., Favier, S., Atassi, F., Barbier, C., Nadaud, S., Lompre, A. M., Hulot, J. S., & Pavoine, C. (2019). Cardiac inflammatory CD11b/c cells exert a protective role in hypertrophied cardiomyocyte by promoting TNFR2- and Orai3- dependent signaling. Science and Reports, 9(1), 6047. https://doi.org/10.1038/s41598-019-42452-yCrossRef

47.

Cao, H., Xiao, C., He, Z., Huang, H., & Tang, H. (2021). IgE and TGF-beta signaling: From immune to cardiac remodeling. Journal of Inflammation Research, 14, 5523–5526. https://doi.org/10.2147/JIR.S332591CrossRefPubMedPubMedCentral

48.

Lovelock, J. D., Monasky, M. M., Jeong, E. M., Lardin, H. A., Liu, H., Patel, B. G., Taglieri, D. M., Gu, L., Kumar, P., Pokhrel, N., Zeng, D., Belardinelli, L., Sorescu, D., Solaro, R. J., & Dudley, S. J. (2012). Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circulation Research, 110(6), 841–850. https://doi.org/10.1161/CIRCRESAHA.111.258251CrossRefPubMedPubMedCentral

49.

Blaustein, M. P., Juhaszova, M., & Golovina, V. A. (1998). The cellular mechanism of action of cardiotonic steroids: A new hypothesis. Clinical and Experimental Hypertension, 20(5–6), 691–703. https://doi.org/10.3109/10641969809053247CrossRefPubMed

50.

Barry, W. H., & Bridge, J. H. (1993). Intracellular calcium homeostasis in cardiac myocytes. Circulation, 87(6), 1806–1815. https://doi.org/10.1161/01.cir.87.6.1806CrossRefPubMed

51.

Zhao, R., Han, C., Dai, S., Wei, S., Xiang, X., Wang, Y., Zhao, R., Zhao, L., & Shan, B. (2021). Inhibitory effects of periplocin on lymphoma cells: A network pharmacology approach and experimental validation. Drug Des Devel Ther, 15, 1333–1344. https://doi.org/10.2147/DDDT.S302221CrossRefPubMedPubMedCentral

Titel: Periplocin Alleviates Cardiac Remodeling in DOCA-Salt–Induced Heart Failure Rats
verfasst von: Jiameng Hao
Liping Chang
Dandong Wang
Chuanyuan Ji
Shaolan Zhang
Yunlong Hou
Yiling Wu
Publikationsdatum: 26.05.2022
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 1/2023
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-022-10277-2

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Periplocin Alleviates Cardiac Remodeling in DOCA-Salt–Induced Heart Failure Rats

Abstract

Graphical abstract

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Human Obesity Attenuates Cardioprotection Conferred by Adipose Tissue–Derived Mesenchymal Stem/Stromal Cells

Single-Dose St. Thomas Versus Custodiol® Cardioplegia for Right Mini-thoracotomy Mitral Valve Surgery

Exosomes in Myocardial Infarction: Therapeutic Potential and Clinical Application

Specific Overexpression of YAP in Vascular Smooth Muscle Attenuated Abdominal Aortic Aneurysm Formation by Activating Elastic Fiber Assembly via LTBP4

NO-Donation Increases Visceral Circulation in a Porcine Model of Abdominal Hypertension

Novel cfDNA Methylation Biomarkers Reveal Delayed Cardiac Cell Death after Open-heart Surgery

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie